Compare CHMI & ORMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHMI | ORMP |
|---|---|---|
| Founded | 2012 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.3M | 117.8M |
| IPO Year | 2013 | N/A |
| Metric | CHMI | ORMP |
|---|---|---|
| Price | $2.72 | $2.95 |
| Analyst Decision | Hold | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $2.75 | N/A |
| AVG Volume (30 Days) | ★ 207.5K | 162.2K |
| Earning Date | 11-06-2025 | 11-13-2025 |
| Dividend Yield | ★ 14.71% | N/A |
| EPS Growth | N/A | ★ 838.25 |
| EPS | 0.02 | ★ 1.03 |
| Revenue | ★ $40,202,000.00 | $2,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $31.73 | N/A |
| P/E Ratio | $145.18 | ★ $2.87 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.17 | $1.82 |
| 52 Week High | $3.68 | $3.24 |
| Indicator | CHMI | ORMP |
|---|---|---|
| Relative Strength Index (RSI) | 67.52 | 57.67 |
| Support Level | $2.47 | $2.83 |
| Resistance Level | $2.78 | $3.24 |
| Average True Range (ATR) | 0.07 | 0.16 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 81.43 | 52.59 |
Cherry Hill Mortgage Investment Corp operates as a real estate investment trust in the United States. It invests in residential mortgage assets to generate current yields and risk-adjusted total returns for its stockholders over the long term, primarily through dividend distributions and secondarily through capital appreciation. The company's reportable segments include investments in Residential mortgage-backed securities (RMBS), Investments in Servicing Related Assets, and All Others. It generates maximum revenue from the RMBS segment in the form of Interest income earned for servicing mortgage loans.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.